Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review

Abstract

AbstractBackgroundParkinson's disease psychosis (PDP) is a multidimensional construct that is challenging to measure. Accurate assessment of PDP requires comprehensive and reliable clinical outcome assessment (COA) measures.ObjectiveTo identify PDP measurement gaps in available COAs currently used in clinical and research settings.MethodsWe conducted a scoping review using Preferred Reporting Items for Systematic Review and Meta‐Analysis Extension for Scoping Reviews (PRISMA‐ScR) guidelines. We implemented a three‐step search strategy in international databases with keywords related to Parkinson's disease (PD), psychosis, and COA. We analyzed studies using COA to assess PDP, classifying their items according to domains and subdomains.ResultsFrom 5673 identified studies, we included 628 containing 432 PDP core items from 32 COAs. Among the 32 COAs, 19 were PD‐specific, containing 266 items, constructed as clinician‐reported outcomes (ClinRO) (148 items), patient‐reported outcomes (PRO) (112 items), and observer‐reported outcomes (ObsRO) (six items). Across all PD‐specific COAs, regardless of structure, 89.4% of the items from 27 COAs focused primarily on assessing PDP symptoms' severity, and only 9.7% of items probed the impact of PDP on a person's daily functioning.ConclusionsSymptom‐based domains are currently prioritized for measuring the severity of PDP, with limited coverage of the functional impact of PDP on patients' lives. Whereas the International Parkinson and Movement Disorder Society has traditionally developed a “Unified” COA that culls items from prior COAs to form a new one, a new COA will largely need newly developed items if the functional impact of PDP is prioritized. © 2024 International Parkinson and Movement Disorder Society.